receiving any pharmacologic treatment. In this group, the panel considered that the potential toxicities of continuous NSAID treatment outweighed the uncertain benefit of less radiographic progression. On-demand treatment should be considered for short-term symptom recurrences (flares). In adults with stable AS receiving treatment with TNFi and NSAIDs, we conditionally recommend continuing treatment with TNFi alone over continuing both medications (PICO 11). In adults with stable AS receiving treatment with TNFi and a conventional synthetic antirheumatic drug, we conditionally recommend continuing treatment with TNFi alone over continuing both medications ( No new studies have directly compared outcomes between patients who continued combination treatment and those who discontinued either NSAIDs or a conventional synthetic antirheumatic drug (csARD). The NSAID-sparing potential of etanercept was demonstrated in a recent trial In adults with stable AS receiving treatment with a